Compounds > 3,4-dimethoxyphenylacetonitrile
Page last updated: 2024-12-06

3,4-dimethoxyphenylacetonitrile

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,4-dimethoxyphenylacetonitrile: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID66727
SCHEMBL ID77974
MeSH IDM0105103

Synonyms (75)

Synonym
einecs 202-225-1
brn 1956100
nsc 6324
3,4-dimethoxybenzeneacetonitrile
ai3-23882
acetonitrile, 3,4-dimethoxyphenyl-
acetonitrile, 3,4-(dimethoxyphenyl)-
(3,4-dimethoxy-phenyl)-acetonitrile
BB 0240981
2-(3,4-dimethoxyphenyl)-acetonitrile
nsc6324
93-17-4
acetonitrile,4-(dimethoxyphenyl)-
(3,4-dimethoxyphenyl)acetonitrile
homoveratronitrile
3,4-(dimethoxyphenyl)acetonitrile
acetonitrile,4-dimethoxyphenyl)-
veratryl cyanide
benzeneacetonitrile,4-dimethoxy-
3,4-dimethoxybenzyl cyanide
nsc-6324
wln: nc1r co1 do1
3,4-dimethoxyphenylacetonitrile
acetonitrile, (3,4-dimethoxyphenyl)-
benzeneacetonitrile, 3,4-dimethoxy-
IFLAB1_000888
OPREA1_832287
(3,4-dimethoxyphenyl)acetonitrile, 98%
AKOS000199051
2-(3,4-dimethoxyphenyl)acetonitrile
HMS1414I08
inchi=1/c10h11no2/c1-12-9-4-3-8(5-6-11)7-10(9)13-2/h3-4,7h,5h2,1-2h3
aslsumisaqdoob-uhfffaoysa-
D1887
62c8s706sp ,
ec 202-225-1
4-10-00-01513 (beilstein handbook reference)
unii-62c8s706sp
2-(3,4-dimethoxyphenyl)ethanenitrile
(3,4-dimethoxyphenyl)acetonirile
F0255-0021
FT-0614353
AM20050420
3,4-dimethoxyphenyl acetonitrile
SCHEMBL77974
3,4-dimethoxy-phenyl-acetonitrile
(3,4-dimethoxyphenyl)-acetonitrile
[3,4-bis(methyloxy)phenyl]acetonitrile
3,4-dimethoxyphenyl-acetonitrile
3,4-dimethoxy phenylacetonitrile
3,4-dimethyoxyphenylacetonitrile
3,4-dimethoxy-benzyl cyanide
3.4-dimethoxyphenylacetonitrile
W-100249
1219803-34-5
3,4-methyleneoxyphenyl acetonitrile
mfcd00001911
DTXSID30239220
GS-3047
homoveratronitrile, purum, >=98.0% (gc)
CS-0008419
SY012004
3,4-dimethoxy phenyl acetonitrile
3,4-di methoxyphenylacetonitrile
EN300-20208
STL195409
BBL036932
2-(3,4-dimethoxyphenyl) acetonitrile
Q27263471
2-(2-chloro-acetylamino)-4-(3,4-dimethoxy-phenyl)-thiophene-3-carboxylicacidethylester
(3,4-dimethoxyphenyl)acetonitrile(homoveratronitrile)
3,4-dimethoxyphenylacetonitirle
3,4-dimethoxyphenylacetonitrile-a,a-d2
Z104477288
PD065604
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (66.67)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.38 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		1.9410aromatic ether;
nitrile;
polyether;
tertiary amino compound
cyanides
Cyanides: Inorganic salts of HYDROGEN CYANIDE containing the -CN radical. The concept also includes isocyanides. It is distinguished from NITRILES, which denotes organic compounds containing the -CN radical.. cyanides : Salts and C-organyl derivatives of hydrogen cyanide, HC#N.. isocyanide : The isomer HN(+)#C(-) of hydrocyanic acid, HC#N, and its hydrocarbyl derivatives RNC (RN(+)#C(-)).. cyanide : A pseudohalide anion that is the conjugate base of hydrogen cyanide.		2.3420pseudohalide anionEC 1.9.3.1 (cytochrome c oxidase) inhibitor
acetonitrile
acetonitrile: RN given refers to unlabeled cpd. acetonitrile : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by a methyl group.		2.0610aliphatic nitrile;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
NMR chemical shift reference compound;
polar aprotic solvent
acrylonitrile
[no description available]		2.0610aliphatic nitrile;
volatile organic compound		antifungal agent;
carcinogenic agent;
fungal metabolite;
mutagen;
polar aprotic solvent
ConditionIndicatedRelationship StrengthStudiesTrials
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310